In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chiltern: The CRO Future Is Mid-Sized

Executive Summary

In remaining private, and neither aspiring to become--or to merge into--a global organization, nor interested in being a specialty CRO, Chiltern is bucking the trend of an industry which over the last decade has seen considerable consolidation at the top accompanied by a proliferation of much smaller niche players. The company's strategy of balancing customer-focused, cost efficient services with the ability to run pan-European/US clinical trials seems well-aimed to capture the business of the emerging and mid-size pharmaceutical companies that will likely be the most prolific source of new innovative drugs over the next decade.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts